We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Determining the Safety and Effectiveness of Olanzapine in Children and Adolescents

This study has been terminated.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00183612
First Posted: September 16, 2005
Last Update Posted: January 8, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Institute of Mental Health (NIMH)
Information provided by (Responsible Party):
Maurizio Fava, MD, Massachusetts General Hospital
  Purpose
This study will examine the safety and effectiveness of the antipsychotic drug olanzapine in children and adolescents with bipolar disorder or psychosis.

Condition Intervention
Bipolar Disorder Psychotic Disorders Drug: Olanzapine

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Developmental Pharmacokinetics of Psychotropic Drugs: Olanzapine

Resource links provided by NLM:


Further study details as provided by Maurizio Fava, MD, Massachusetts General Hospital:

Primary Outcome Measures:
  • Olanzapine pharmacokinetics, safety, and effectiveness [ Time Frame: Measured over 8 weeks ]

Estimated Enrollment: 68
Study Start Date: May 2000
Study Completion Date: April 2007
Primary Completion Date: April 2007 (Final data collection date for primary outcome measure)
Detailed Description:

Numerous advancements in mental health treatment have been made over the past decade. Unfortunately, these advancements have focused on adults and have not been fully extended to children and adolescents. With limited pediatric information on the pharmacokinetics and pharmacodynamics for drugs used to treat mental health problems, psychiatrists are prescribing drugs for children using data extrapolated from adults, which may lead to potentially life-threatening results. Olanzapine is widely prescribed to treat both children and adults. This study will determine the safety and effectiveness of olanzapine in children and adolescents with mental health disorders. The study will also compare the effects of gender, development, body composition, and metabolic genotype and phenotype on how olanzapine works.

All participants will receive olanzapine for up to 8 weeks. Blood collection will occur at each weekly study visit. On Visit 1, participants will receive their first dose of olanzapine and repeated blood collection will occur every hour for 24 hours. Blood collection will be used to determine the time it takes for olanzapine to be absorbed into the body, its duration of action, the extent of its distribution in the body, the manner in which it is excreted from the body, and its effects on organs of the body.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   6 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of bipolar disorder with mania, mixed mania, or psychosis not otherwise specified
  • Meet certain laboratory result requirements
  • Have taken either lithium or valproate for 4 weeks or longer with no or only partial response
  • Parent or guardian willing to provide informed consent

Exclusion Criteria:

  • History of other serious unstable illness requiring medication
  • Diabetes mellitus
  • Abnormal physical examination and electrocardiogram (EKG) results
  • At risk for suicide or homicide (based on an assessment of suicidal history, intent or plan, mental state, mood, and substance use)
  • IQ less than 65
  • History of organic brain disease or seizure disorder
  • Recent exposure to an infectious disease, such as tuberculosis (TB) or meningitis
  • Current use of drugs that may interfere with the metabolism of olanzapine and unwilling to discontinue use during the study
  • Body mass index (BMI) less than the 5th OR greater than the 95th percentile for age and gender
  • History of smoking within 1 year prior to study entry
  • Pregnancy or breastfeeding
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00183612


Locations
United States, Massachusetts
McLean Hospital
Belmont, Massachusetts, United States, 02478
Cambridge Health Alliance
Medford, Massachusetts, United States, 02155
Sponsors and Collaborators
Massachusetts General Hospital
National Institute of Mental Health (NIMH)
Investigators
Principal Investigator: Louise G. Cohen, PharmD Massachusetts General Hospital
  More Information

Responsible Party: Maurizio Fava, MD, MD, Massachusetts General Hospital
ClinicalTrials.gov Identifier: NCT00183612     History of Changes
Other Study ID Numbers: K08MH001765 ( U.S. NIH Grant/Contract )
DSIR CT-M
First Submitted: September 13, 2005
First Posted: September 16, 2005
Last Update Posted: January 8, 2014
Last Verified: January 2014

Keywords provided by Maurizio Fava, MD, Massachusetts General Hospital:
Child
Adolescent
Mental Health
Olanzapine
Pharmacokinetics
Pharmacology

Additional relevant MeSH terms:
Disease
Bipolar Disorder
Psychotic Disorders
Mental Disorders
Pathologic Processes
Bipolar and Related Disorders
Schizophrenia Spectrum and Other Psychotic Disorders
Olanzapine
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents


To Top